Pirlindole
Clinical data
Trade namesPirazidol
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20–30%
Protein binding95%
Metabolismhepatic
Onset of action2 to 8 hours
Elimination half-lifeup to 8 days [1]
Excretionurine (50–70%), feces (25–45%)
Identifiers
  • 8-methyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H18N2
Molar mass226.323 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(C=C1)N3CCNC4C3=C2CCC4

Pirlindole (Lifril, Pyrazidol) is mainly a reversible inhibitor of monoamine oxidase A (RIMA) and secondly a SNRI which was developed and is used in Russia as an antidepressant.[2] It is structurally and pharmacologically related to metralindole.

See also

References

  1. ^ Pöldinger W (1985). "Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline.". Psychiatry the State of the Art. Boston, MA.: Springer. pp. 283–289. doi:10.1007/978-1-4613-2363-1_44. ISBN 978-1-4613-2363-1.
  2. ^ Bruhwyler, J.; Liégeois, J.F.; Géczy, J. (July 1997). "PIRLINDOLE: A SELECTIVE REVERSIBLE INHIBITOR OF MONOAMINE OXIDASE A. A REVIEW OF ITS PRECLINICAL PROPERTIES". Pharmacological Research. 36 (1): 23–33. doi:10.1006/phrs.1997.0196.